In conclusion, coexisting mutations in SMAD4 and TP53 are associated with worse overall survival than concurrent TP53 wild-type SMAD4 mutation patients with metastatic colorectal cancer. This evidence concerns the gene TP53 and metastatic colorectal cancer.